Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer

J. Mortimer, R. B. Livingston, I. J. Hardesty, C. W. Groppe, J. D. Purvis, M. Gupta, N. Flournoy

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Twenty-seven women with disseminated estrogen receptor-negative breast cancer received an aggressive chemotherapy program of prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide. Responses were achieved in 21 of 26 (81%) evaluable patients, eight (31%) of whom had complete responses. The median survival was 17 months. Despite the favorable overall response and a significant number of complete responses, all patients eventually relapsed. Although most patients relapsed systemically, two relapsed initially in the CNS.

Original languageEnglish (US)
Pages (from-to)1017-1018
Number of pages2
JournalCancer Treatment Reports
Volume68
Issue number7-8
StatePublished - Oct 18 1984

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer'. Together they form a unique fingerprint.

Cite this